LAPd, lipoic acid-palladium complex, Palladium-alpha-lipoic acid complex
Polydox is a synthetic product containing lipoic acid-palladium complex (LAPd) and B complex vitamins. Patients use it to treat cancer, HIV/AIDS, chronic fatigue syndrome, psoriasis, and other degenerative disorders. Studies done in animals indicate that Polydox has neuroprotective (3), radioproctective (4), antidiabetic (7) and antioxidant (5) (6) properties.
This product has not been evaluated in clinical trials.
- Cancer treatment
- Chronic fatigue syndrome
- HIV and AIDS
- Systemic lupus erythematosus (SLE)
- Palladium α-lipoic acid complex (1:1) 3.72 × 10−2 mmol/L
- Thiamine 2.17 × 10−3 mmol/L
- N-acetyl cysteine 1.13 × 10−3 mmol/L
- Riboflavin 4.62 × 10−4 mmol/L
- N-formyl methionine 1.46 × 10−4 mmol/L
- Cyanocobalamin (Vitamin B12) 1.37 × 10−4 mmol/L
- Rhodium 1.34 × 10−4 mmol/L
- Molybdenum 4.63 × 10−4 mmol/L
- Ruthenium 1.42 × 10−5 mmol/L
- Sodium chloride 2.64 × 10−1 mmol/L
Mechanism of Action
The inventor claims that Polydox is a metalo-vitamin; with antioxidant activity capable of repairing damaged genes. Polydox is said to have DNA reductase and electro-active; properties that alter electron flow in cancer cells at the mitochondrial level, resulting in cytotoxicity. The manufacturer reports benefits for cancer patients such as increases in energy and appetite, reduction in cancer-related pain (1) (2). However, no independent scientific data support these claims. Studies in rats show palladium-alpha-lipoic acid complex protects the aging of myocardium by enhancing the Krebs cycle dehydrogenases and mitochondrial electron transport chain complexes (5). It increases the level of glutathione and reduces the level of lipid peroxidation (6) (7). Palladium-alpha-lipoic acid complex also protect against radiation-induced cellular damages in animals (4).
The manufacturer claims that Polydox distributes throughout the body to all sites, including adipose tissue and the central nervous system. No formal pharmacokinetics studies have been performed.
Polydox's antioxidant activity may interfere with the actions of certain chemotherapeutic agents.
Literature Summary and Critique
Human studies have not been conducted.
Dosage (Inside MSKCC Only)
This field is only visible to only Inside MSKCC users.
- Polymva. American Medicine and Research Center web site. Available at http://www.polymva.com. Accessed February 23, 2011.
- Garnett M. Palladium complexes and methods for using same in the treatment of tumors. Garnett McKeen Laboratory, Inc. US Patent #5,679,697. October 21, 1997.
- Antonawich FJ, Fiore SM, Welicky LM. Regulation of ischemic cell death by the lipoic acid-palladium complex, Poly MVA, in gerbils. Exp Neurol.2004 Sep;189(1):10-5.
- Ramachandran L, Krishnan CV, Nair CK. Radioprotection by alpha-lipoic acid palladium complex formulation (POLY-MVA) in mice. Cancer Biother Radiopharm. 2010 Aug;25(4):395-9.
- Sudheesh NP, Ajith TA, Janardhanan KK, Krishnan CV. Palladium alpha-lipoic acid complex formulation enhances activities of Krebs cycle dehydrogenases and respiratory complexes I-IV in the heart of aged rats. Food Chem Toxicol. 2009;47(8):2124-8.
- Sudheesh NP, Ajith TA, Janardhanan KK, Krishnan CV. Effect of POLY-MVA, a palladium alpha-lipoic acid complex formulation against declined mitochondrial antioxidant status in the myocardium of aged rats. Food Chem Toxicol. 2010;48(7):1858-62.
- Sudheesh NP, Ajith TA, Janardhanan KK, et al. Palladium-α-lipoic acid complex attenuates alloxan-induced hyperglycemia and enhances the declined blood antioxidant status in diabetic rats. J Diabetes. 2011 Dec;3(4):293-300.